Registration: 144A/Reg S; Comments: 01/28/2020 Cheplapharm Arzneimitel GmbH EUR500m (up from EUR400m) 144A/Reg S sr sec notes due 11-Feb-2027 (7y). NC3 (MWC B+50bp), then at 101.750, 10.875, 100. Equity claw: 3y 40% at 102.50. Special call: 10% per year the first 3 years at 103. B2/B/BB- (stable/stable/stable). Via DB (B&D)/JPM joint glocos/HSBC/UniCredit joint books. No reg rights. List ISE. New York law. Settles Feb 11 (T+10). Reg S ISIN: SX2112973107. Px talk: 3.50-3.75%. Launched: EUR500m at 3.50%. Priced: 3.50% at 100. +405bp vs DBR 0.25% due 15-Feb-2027. Roadshow Jan 24-28 (Fri Frankfurt, Mon London City lunch, Tuesday London West End breakfast). Books close at 2:30pm UK Jan 28. UOP: along with a new EUR980m (EUR100m increase was dropped) term loan B, to refi its existing EUR980m term loan B, pay down revolver ($145m) and repay $112m bridge loan incurred to finance the acquisition of four oncology and incontinence products from Sanofi (the Gold Portfolio) for EUR66.5m and the global commercial rights for Losec (omerprazole) from AstraXenaca for $243m, and to fund the upcoming acquisition of ten cardiology and intensive care products from Sanofi for EUR102m (the Sake Acquisition). Biz: leading market player in branded off-patent specialty and niche pharmaceutical market. HQ: Greifswald, Germany.;